<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540293</url>
  </required_header>
  <id_info>
    <org_study_id>A2581157</org_study_id>
    <nct_id>NCT00540293</nct_id>
  </id_info>
  <brief_title>Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study</brief_title>
  <acronym>AT GOAL</acronym>
  <official_title>A Multicenter, Eight-Week Treatment, Single-Step Titration Open-Label Study Assessing The Percentage Of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Doses Of 10 MG, 20 MG, And 40 MG.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the percentage of Korean dyslipidemic subjects in the total group and each
      cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at
      starting doses of 10mg, 20mg and 40mg of atorvastatin after 8 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment.</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment.</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment</measure>
    <time_frame>Weeks 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment</measure>
    <time_frame>weeks 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment</measure>
    <time_frame>4 and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.</measure>
    <time_frame>Baseline, and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">425</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this patient group consists of dyslipidemia patients with various CVD risk factors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a Korean , dyslipidemic outpatient

          2. Is eligible for LDL-lowering drug therapy at screening and baseline as determined by
             the following LDL-cholesterol (LDL-C) cut-off points defined by NCEP ATP Ⅲ: 2. 1 LDL-C
             ≥ 190 mg/dL for subjects with 0 or 1 CHD risk factor 2. 2 LDL-C ≥ 160 mg/dL for
             subjects with 2 or more CHD risk factors and 10 year risk &lt; 10 % 2. 3 LDL-C ≥ 130
             mg/dL for subjects with 2 or more CHD risk factors and 10 year risk 10-20 % 2. 4 LDL-C
             ≥ 100 mg/dL for subjects with documented CHD or CHD risk equivalents (10-year risk &gt;
             20 %)

          3. Has LDL-C ≤ 220mg/dL at baseline 4. Has triglyceride level ≤ 600mg/dL at baseline

        Exclusion Criteria:

          1. Is pregnant or lactating

          2. Has present myopathy or history of myopathy or has personal or familial history of
             hereditary muscular disorders or any history of rhabdomyolysis

          3. Has history of intolerance or hypersensitivity to atorvastatin or other statins

          4. Uncontrolled hypertension (i.e. moderate hypertension, sitting systolic BP ≥ 160mmHg
             and/or diastolic BP ≥ 100mmHg)

          5. Has HbAlc &gt; 10%

          6. Has any severe disease of has had any major problem or surgical procedure within the 3
             months prior to screening that is likely to jeopardize the planned termination of the
             study. (e.g., any carcinoma, coronary angioplasty, coronary artery bypass graft,
             cardiac infarct, severe or unstable angina pectoris)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daegu</city>
        <state>Korea</state>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daejeon</city>
        <zip>302-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <zip>503-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kyunggi-do</city>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>134-010</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>143-914</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A2581157&amp;StudyName=Lipitor%20Korean%20Atorvastatin%20Goal%20Achievement%20Across%20Risk%20Levels%20Study</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <results_first_submitted>May 8, 2009</results_first_submitted>
  <results_first_submitted_qc>May 8, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2009</results_first_posted>
  <last_update_submitted>August 14, 2009</last_update_submitted>
  <last_update_submitted_qc>August 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted at 20 centers in Korea</recruitment_details>
      <pre_assignment_details>Participants who were on antilipidemic medications at the time of screening required a 6-week washout period prior to study treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Total Treatment Group (All Subjects Who Received Atorvastatin)</title>
          <description>this patient group consists of dyslipidemia patients with various cardiovascular diseases (CVD)risk factors</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="390"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse event related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event not related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol violation, &amp; subject schedule</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Treatment Group (All Subjects Who Received Atorvastatin)</title>
          <description>this patient group consists of dyslipidemia patients with various cardiovascular diseases (CVD)risk factors</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="425"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Females between 18 and 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Males between 18 and 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment.</title>
        <description>LDL-C Responders by visit and by risk group - FAS</description>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total=sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29 (Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 ( Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment.</title>
          <description>LDL-C Responders by visit and by risk group - FAS</description>
          <units>Percent subjects achieved LDL-C target</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" lower_limit="77.9" upper_limit="85.5"/>
                    <measurement group_id="O2" value="85.7" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O3" value="95.5" lower_limit="84.5" upper_limit="99.4"/>
                    <measurement group_id="O4" value="79.9" lower_limit="75.2" upper_limit="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment</title>
        <description>Mean baseline, change and percent change from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride</description>
        <time_frame>Weeks 4 and 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total=sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29 (Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 (Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment</title>
          <description>Mean baseline, change and percent change from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride</description>
          <units>mg/dL (ratio for Scalar)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.7" lower_limit="149.1" upper_limit="154.4"/>
                    <measurement group_id="O2" value="187.0" lower_limit="179.8" upper_limit="194.1"/>
                    <measurement group_id="O3" value="160.6" lower_limit="154.3" upper_limit="167.0"/>
                    <measurement group_id="O4" value="147.7" lower_limit="144.9" upper_limit="150.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.5" lower_limit="-66.2" upper_limit="-60.8"/>
                    <measurement group_id="O2" value="-73.8" lower_limit="-82.7" upper_limit="-64.8"/>
                    <measurement group_id="O3" value="-65.1" lower_limit="-73.5" upper_limit="-56.7"/>
                    <measurement group_id="O4" value="-62.4" lower_limit="-65.4" upper_limit="-59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.3" lower_limit="-68.0" upper_limit="-62.5"/>
                    <measurement group_id="O2" value="-77.6" lower_limit="-88.3" upper_limit="-66.9"/>
                    <measurement group_id="O3" value="-64.2" lower_limit="-72.4" upper_limit="-56.0"/>
                    <measurement group_id="O4" value="-64.4" lower_limit="-67.4" upper_limit="-61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="47.3" upper_limit="49.3"/>
                    <measurement group_id="O2" value="50.5" lower_limit="47.4" upper_limit="53.7"/>
                    <measurement group_id="O3" value="48.0" lower_limit="45.5" upper_limit="50.5"/>
                    <measurement group_id="O4" value="48.2" lower_limit="47.0" upper_limit="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.7" upper_limit="0.9"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-3.6" upper_limit="2.0"/>
                    <measurement group_id="O3" value="3.3" lower_limit="0.9" upper_limit="5.7"/>
                    <measurement group_id="O4" value="-0.2" lower_limit="-1.1" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-0.4" upper_limit="1.3"/>
                    <measurement group_id="O2" value="2.1" lower_limit="-1.6" upper_limit="5.9"/>
                    <measurement group_id="O3" value="3.0" lower_limit="0.9" upper_limit="5.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.5" lower_limit="172.5" upper_limit="178.5"/>
                    <measurement group_id="O2" value="209.9" lower_limit="201.0" upper_limit="218.8"/>
                    <measurement group_id="O3" value="187.1" lower_limit="179.9" upper_limit="194.4"/>
                    <measurement group_id="O4" value="171.1" lower_limit="167.9" upper_limit="174.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.4" lower_limit="-72.3" upper_limit="-66.5"/>
                    <measurement group_id="O2" value="-75.4" lower_limit="-87.8" upper_limit="-63.1"/>
                    <measurement group_id="O3" value="-71.3" lower_limit="-80.2" upper_limit="-62.5"/>
                    <measurement group_id="O4" value="-68.6" lower_limit="-71.8" upper_limit="-65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.7" lower_limit="-73.7" upper_limit="-67.7"/>
                    <measurement group_id="O2" value="-80.9" lower_limit="-93.9" upper_limit="-67.8"/>
                    <measurement group_id="O3" value="-72.1" lower_limit="-80.3" upper_limit="-64.0"/>
                    <measurement group_id="O4" value="-69.7" lower_limit="-73.0" upper_limit="-66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C/HDL-C ratio baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="3.1" upper_limit="3.3"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.4" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.4" lower_limit="3.2" upper_limit="3.6"/>
                    <measurement group_id="O4" value="3.2" lower_limit="3.1" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C/HDL-C Ratio (Scalar) week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-1.4" upper_limit="-1.3"/>
                    <measurement group_id="O2" value="-1.4" lower_limit="-1.7" upper_limit="-1.1"/>
                    <measurement group_id="O3" value="-1.5" lower_limit="-1.7" upper_limit="-1.3"/>
                    <measurement group_id="O4" value="-1.3" lower_limit="-1.4" upper_limit="-1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C/HDL-C Ratio (Scalar) week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-1.5" upper_limit="-1.3"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-1.9" upper_limit="-1.2"/>
                    <measurement group_id="O3" value="-1.5" lower_limit="-1.7" upper_limit="-1.3"/>
                    <measurement group_id="O4" value="-1.4" lower_limit="-1.5" upper_limit="-1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.9" lower_limit="220.8" upper_limit="227.0"/>
                    <measurement group_id="O2" value="262.3" lower_limit="253.9" upper_limit="270.8"/>
                    <measurement group_id="O3" value="235.1" lower_limit="228.0" upper_limit="242.3"/>
                    <measurement group_id="O4" value="219.3" lower_limit="216.0" upper_limit="222.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.4" lower_limit="-72.4" upper_limit="-66.4"/>
                    <measurement group_id="O2" value="-78.2" lower_limit="-89.3" upper_limit="-67.1"/>
                    <measurement group_id="O3" value="-68.0" lower_limit="-77.2" upper_limit="-58.8"/>
                    <measurement group_id="O4" value="-68.8" lower_limit="-72.2" upper_limit="-65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.4" lower_limit="-73.4" upper_limit="-67.3"/>
                    <measurement group_id="O2" value="-80.7" lower_limit="-94.2" upper_limit="-67.3"/>
                    <measurement group_id="O3" value="-69.1" lower_limit="-77.2" upper_limit="-61.1"/>
                    <measurement group_id="O4" value="-69.7" lower_limit="-73.1" upper_limit="-66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.1" lower_limit="146.2" upper_limit="162.1"/>
                    <measurement group_id="O2" value="150.7" lower_limit="128.6" upper_limit="172.8"/>
                    <measurement group_id="O3" value="152.3" lower_limit="130.3" upper_limit="174.2"/>
                    <measurement group_id="O4" value="154.7" lower_limit="145.6" upper_limit="163.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.1" lower_limit="-35.5" upper_limit="-22.7"/>
                    <measurement group_id="O2" value="-11.5" lower_limit="-43.0" upper_limit="20.0"/>
                    <measurement group_id="O3" value="-16.6" lower_limit="-31.4" upper_limit="-1.8"/>
                    <measurement group_id="O4" value="-32.1" lower_limit="-39.2" upper_limit="-25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.3" lower_limit="-37.9" upper_limit="-20.7"/>
                    <measurement group_id="O2" value="-20.9" lower_limit="-51.3" upper_limit="9.5"/>
                    <measurement group_id="O3" value="-18.5" lower_limit="-36.3" upper_limit="-0.7"/>
                    <measurement group_id="O4" value="-31.4" lower_limit="-41.3" upper_limit="-21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment</title>
        <description>Mean percent changes from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride</description>
        <time_frame>weeks 4 and 8</time_frame>
        <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total=sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29 (Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 ( Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment</title>
          <description>Mean percent changes from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride</description>
          <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDL-C % change from baseline (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.9" lower_limit="-42.3" upper_limit="-39.5"/>
                    <measurement group_id="O2" value="-39.5" lower_limit="-44.1" upper_limit="-35.0"/>
                    <measurement group_id="O3" value="-39.6" lower_limit="-43.8" upper_limit="-35.5"/>
                    <measurement group_id="O4" value="-41.2" lower_limit="-42.8" upper_limit="-39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C % change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.0" lower_limit="-43.4" upper_limit="-40.7"/>
                    <measurement group_id="O2" value="-41.2" lower_limit="-46.6" upper_limit="-35.8"/>
                    <measurement group_id="O3" value="-39.3" lower_limit="-43.5" upper_limit="-35.1"/>
                    <measurement group_id="O4" value="-42.5" lower_limit="-44.0" upper_limit="-41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C % change from baseline (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="3.4"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-6.0" upper_limit="5.6"/>
                    <measurement group_id="O3" value="7.7" lower_limit="2.3" upper_limit="13.1"/>
                    <measurement group_id="O4" value="1.1" lower_limit="-0.8" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C % change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.8" upper_limit="4.4"/>
                    <measurement group_id="O2" value="5.6" lower_limit="-2.1" upper_limit="13.2"/>
                    <measurement group_id="O3" value="6.7" lower_limit="2.3" upper_limit="11.1"/>
                    <measurement group_id="O4" value="1.8" lower_limit="-0.2" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C % change from baseline (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.7" lower_limit="-40.1" upper_limit="-37.4"/>
                    <measurement group_id="O2" value="-35.5" lower_limit="-40.9" upper_limit="-30.1"/>
                    <measurement group_id="O3" value="-37.7" lower_limit="-41.5" upper_limit="-33.8"/>
                    <measurement group_id="O4" value="-39.1" lower_limit="-40.6" upper_limit="-37.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C % change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.4" lower_limit="-40.7" upper_limit="-38.1"/>
                    <measurement group_id="O2" value="-38.2" lower_limit="-44.1" upper_limit="-32.2"/>
                    <measurement group_id="O3" value="-38.3" lower_limit="-42.1" upper_limit="-34.5"/>
                    <measurement group_id="O4" value="-39.7" lower_limit="-41.1" upper_limit="-38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C/HDL-C ratio % change from baseline (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.3" lower_limit="-43.0" upper_limit="-39.7"/>
                    <measurement group_id="O2" value="-36.7" lower_limit="-44.3" upper_limit="-29.0"/>
                    <measurement group_id="O3" value="-44.1" lower_limit="-48.9" upper_limit="-39.3"/>
                    <measurement group_id="O4" value="-41.4" lower_limit="-43.2" upper_limit="-39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C/HDL-C ratio % change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.6" lower_limit="-44.3" upper_limit="-40.9"/>
                    <measurement group_id="O2" value="-41.6" lower_limit="-49.5" upper_limit="-33.7"/>
                    <measurement group_id="O3" value="-42.9" lower_limit="-48.0" upper_limit="-37.7"/>
                    <measurement group_id="O4" value="-42.6" lower_limit="-44.5" upper_limit="-40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC % change from baseline (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.3" lower_limit="-31.4" upper_limit="-29.2"/>
                    <measurement group_id="O2" value="-29.7" lower_limit="-33.6" upper_limit="-25.7"/>
                    <measurement group_id="O3" value="-28.5" lower_limit="-31.9" upper_limit="-25.2"/>
                    <measurement group_id="O4" value="-30.6" lower_limit="-31.9" upper_limit="-29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC % change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.7" lower_limit="-31.9" upper_limit="-29.6"/>
                    <measurement group_id="O2" value="-30.4" lower_limit="-35.2" upper_limit="-25.5"/>
                    <measurement group_id="O3" value="-29.2" lower_limit="-32.3" upper_limit="-26.2"/>
                    <measurement group_id="O4" value="-31.0" lower_limit="-32.2" upper_limit="-29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG % change from baseline (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" lower_limit="-12.9" upper_limit="-3.6"/>
                    <measurement group_id="O2" value="4.4" lower_limit="-18.5" upper_limit="27.3"/>
                    <measurement group_id="O3" value="-8.3" lower_limit="-17.7" upper_limit="1.2"/>
                    <measurement group_id="O4" value="-9.3" lower_limit="-14.4" upper_limit="-4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG % change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" lower_limit="-14.9" upper_limit="-4.8"/>
                    <measurement group_id="O2" value="-6.3" lower_limit="-27.0" upper_limit="14.5"/>
                    <measurement group_id="O3" value="-7.0" lower_limit="-20.4" upper_limit="6.4"/>
                    <measurement group_id="O4" value="-10.5" lower_limit="-16.2" upper_limit="-4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.</title>
        <description>LDL-C responders at week 8 by titration status and risk groups - FAS, efficacy evaluation (EVAL), and FAS (no last observation carried forward, LOCF)</description>
        <time_frame>8 weeks</time_frame>
        <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total=sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29(Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 (Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.</title>
          <description>LDL-C responders at week 8 by titration status and risk groups - FAS, efficacy evaluation (EVAL), and FAS (no last observation carried forward, LOCF)</description>
          <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FAS population responders no titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS population responders 1-step titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EVAL population responders no titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EVAL population responders 1-step titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS population (no LOCF) no titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS population (no LOCF) 1-step titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.</title>
        <description>LDL-C responders at week 8 by titration status and risk groups - FAS, efficay evaluation (EVAL), and FAS (no last observation carried forward, LOCF)</description>
        <time_frame>8 weeks</time_frame>
        <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total=sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29 (Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 ( Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.</title>
          <description>LDL-C responders at week 8 by titration status and risk groups - FAS, efficay evaluation (EVAL), and FAS (no last observation carried forward, LOCF)</description>
          <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FAS population, no titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" lower_limit="85.3" upper_limit="92.2"/>
                    <measurement group_id="O2" value="95.8" lower_limit="78.9" upper_limit="99.9"/>
                    <measurement group_id="O3" value="97.6" lower_limit="87.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="87.2" lower_limit="82.7" upper_limit="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS population, 1-step titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1" lower_limit="69.6" upper_limit="91.1"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="80.8" lower_limit="67.5" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EVAL population, no titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" lower_limit="87.4" upper_limit="94.1"/>
                    <measurement group_id="O2" value="95.5" lower_limit="77.2" upper_limit="99.9"/>
                    <measurement group_id="O3" value="97.4" lower_limit="86.5" upper_limit="99.9"/>
                    <measurement group_id="O4" value="89.8" lower_limit="85.2" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EVAL population, 1-step titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" lower_limit="70.2" upper_limit="91.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="81.6" lower_limit="68.0" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS population (no LOCF), no titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.0" lower_limit="85.1" upper_limit="92.1"/>
                    <measurement group_id="O2" value="95.8" lower_limit="78.9" upper_limit="99.9"/>
                    <measurement group_id="O3" value="97.6" lower_limit="87.1" upper_limit="99.9"/>
                    <measurement group_id="O4" value="87.1" lower_limit="82.5" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FAS population (no LOCF), 1-step titration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.1" lower_limit="69.6" upper_limit="91.1"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="80.8" lower_limit="67.5" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment</title>
        <description>Median baseline, and change from baseline in hs-CRP by risk group - FAS</description>
        <time_frame>4 and 8 weeks</time_frame>
        <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total=sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29(Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 (Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment</title>
          <description>Median baseline, and change from baseline in hs-CRP by risk group - FAS</description>
          <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.108" lower_limit="0.094" upper_limit="0.126"/>
                    <measurement group_id="O2" value="0.082" lower_limit="0.060" upper_limit="0.112"/>
                    <measurement group_id="O3" value="0.075" lower_limit="0.059" upper_limit="0.126"/>
                    <measurement group_id="O4" value="0.122" lower_limit="0.102" upper_limit="0.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change from baseline (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" lower_limit="-0.014" upper_limit="-0.005"/>
                    <measurement group_id="O2" value="-0.008" lower_limit="-0.028" upper_limit="-0.001"/>
                    <measurement group_id="O3" value="-0.002" lower_limit="-0.014" upper_limit="0.023"/>
                    <measurement group_id="O4" value="-0.010" lower_limit="-0.018" upper_limit="-0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" lower_limit="-0.021" upper_limit="-0.009"/>
                    <measurement group_id="O2" value="-0.011" lower_limit="-0.034" upper_limit="0.018"/>
                    <measurement group_id="O3" value="-0.001" lower_limit="-0.021" upper_limit="0.010"/>
                    <measurement group_id="O4" value="-0.018" lower_limit="-0.027" upper_limit="-0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment.</title>
        <description>LDL-C Responders by visit and by risk group - full analysis set (FAS)</description>
        <time_frame>Week 8</time_frame>
        <population>N=number of subjects in the Full Analysis Set (FAS). Number of Participants Analyzed represents subjects with on-treatment lipid measures (missing values imputed by last observation carried forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total: sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29 (Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 (Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment.</title>
          <description>LDL-C Responders by visit and by risk group - full analysis set (FAS)</description>
          <population>N=number of subjects in the Full Analysis Set (FAS). Number of Participants Analyzed represents subjects with on-treatment lipid measures (missing values imputed by last observation carried forward)</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.0" lower_limit="82.3" upper_limit="89.2"/>
                    <measurement group_id="O2" value="92.9" lower_limit="76.5" upper_limit="99.1"/>
                    <measurement group_id="O3" value="95.5" lower_limit="84.5" upper_limit="99.4"/>
                    <measurement group_id="O4" value="84.3" lower_limit="80.0" upper_limit="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment</title>
        <description>Percent change from baseline in hs-CRP by risk group - FAS</description>
        <time_frame>4 and 8 weeks</time_frame>
        <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total=sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29 (Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 ( Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment</title>
          <description>Percent change from baseline in hs-CRP by risk group - FAS</description>
          <population>Laboratory Population: 10 subjects from FAS (n=425) were not included in Laboratory Population (n=415).</population>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median % change from baseline (week 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.346" lower_limit="-21.429" upper_limit="-4.651"/>
                    <measurement group_id="O2" value="-13.941" lower_limit="-35.055" upper_limit="-1.923"/>
                    <measurement group_id="O3" value="-2.553" lower_limit="-22.951" upper_limit="25.926"/>
                    <measurement group_id="O4" value="-16.197" lower_limit="-24.182" upper_limit="-4.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median % change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.605" lower_limit="-24.138" upper_limit="-11.111"/>
                    <measurement group_id="O2" value="-18.621" lower_limit="-37.363" upper_limit="20.690"/>
                    <measurement group_id="O3" value="-1.472" lower_limit="-26.364" upper_limit="14.925"/>
                    <measurement group_id="O4" value="-20.561" lower_limit="-25.333" upper_limit="-12.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.</title>
        <description>Median baseline, and change from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS</description>
        <time_frame>Baseline, and 8 weeks</time_frame>
        <population>Laboratory Population: 17 subjects from FAS (n=425) were not included in Laboratory Population (n=408).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total=sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29(Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 (Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.</title>
          <description>Median baseline, and change from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS</description>
          <population>Laboratory Population: 17 subjects from FAS (n=425) were not included in Laboratory Population (n=408).</population>
          <units>pg/dL</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCP-1 baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.7" lower_limit="295.0" upper_limit="311.7"/>
                    <measurement group_id="O2" value="305.2" lower_limit="267.9" upper_limit="340.6"/>
                    <measurement group_id="O3" value="317.7" lower_limit="294.2" upper_limit="386.4"/>
                    <measurement group_id="O4" value="301.6" lower_limit="291.7" upper_limit="310.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1 change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="21.3" upper_limit="66.7"/>
                    <measurement group_id="O2" value="-15.0" lower_limit="-61.4" upper_limit="45.9"/>
                    <measurement group_id="O3" value="-22.4" lower_limit="-102.9" upper_limit="42.6"/>
                    <measurement group_id="O4" value="59.4" lower_limit="33.6" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.40" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.30" lower_limit="0.10" upper_limit="0.60"/>
                    <measurement group_id="O3" value="0.40" lower_limit="0.30" upper_limit="0.80"/>
                    <measurement group_id="O4" value="0.50" lower_limit="0.40" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.30" upper_limit="0.00"/>
                    <measurement group_id="O3" value="-0.10" lower_limit="-0.30" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-alpha baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="0.10" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.10" upper_limit="0.30"/>
                    <measurement group_id="O3" value="0.20" lower_limit="0.10" upper_limit="0.30"/>
                    <measurement group_id="O4" value="0.10" lower_limit="0.10" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-alpha change from baseline (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.10" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-0.10" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.</title>
        <description>Percent changes from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS</description>
        <time_frame>8 weeks</time_frame>
        <population>Laboratory Population: 17 subjects from FAS (n=425) were not included in Laboratory Population (n=408).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>N=425 (Total=sum of all risk groups)</description>
          </group>
          <group group_id="O2">
            <title>Low Risk</title>
            <description>N=29 (Low Risk: Subjects with 0 or 1 CHD risk factor (who were assumed to have 10-year risk for CHD &lt; 10%) or subjects with 2 or more CHD risk factors and 10-year risk for CHD &lt; 10 %, e.g., subjects in Category 1 or 2.)</description>
          </group>
          <group group_id="O3">
            <title>Medium Risk</title>
            <description>N=45 ( Medium Risk: Subjects with 2 or more CHD risk factors and 10-year risk for CHD 10-20 %, e.g., subjects in Category 3.)</description>
          </group>
          <group group_id="O4">
            <title>High Risk</title>
            <description>N=351 (High Risk: Subjects with CHD, CHD risk equivalent or with 2 or more risk factors conferring a 10 year risk &gt; 20 %, e.g., subjects in Category 4.)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.</title>
          <description>Percent changes from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS</description>
          <population>Laboratory Population: 17 subjects from FAS (n=425) were not included in Laboratory Population (n=408).</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="337"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCP-1 % change (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="7.8" upper_limit="22.3"/>
                    <measurement group_id="O2" value="-5.6" lower_limit="-18.6" upper_limit="18.7"/>
                    <measurement group_id="O3" value="-8.0" lower_limit="-34.2" upper_limit="21.4"/>
                    <measurement group_id="O4" value="18.2" lower_limit="11.1" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 % change (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-50.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="-12.50" lower_limit="-45.45" upper_limit="25.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-alpha % change (week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-50.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-42.86" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Total Treatment Group (All Subjects Who Received Atorvastatin)</title>
          <description>this patient group consists of dyslipidemia patients with various cardiovascular diseases (CVD)risk factors</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerabral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt;60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt;12 mo from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

